PatientsVille.com Logo


Tositumomab Medical Research Studies

Up-to-date List of Tositumomab Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Tositumomab Medical Research Studies

Rank Status Study
1 Unknown  Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Disease
Intervention: Drug: I-131 Tositumomab therapeutic regimen
Outcome Measures: Non-myeloablative maximum tolerated dose of I-131 Tositumomab that can be given to patients with relapsed/refractory Hodgkin's lymphoma who are post or ineligible for transplant;   Overall and complete response rates;   Duration of response of Hodgkin's lymphoma to I-131 Tositumomab;   Frequency of visualization of Hodgkin's lymphoma with I-131 Tositumomab imaging and tumor radiation absorbed dose
2 Recruiting Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Low dose methotrexate and Bexxar
Outcome Measures: determination of the rate of HAMA (human anti-mouse antibody) conversion following treatment;   Response rates. overall, complete, and partial response rates to this therapy.;   progression-free and overall survival rates
3 Unknown  A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Rituximab or Iodine I 131 Tositumomab Therapy
Outcome Measure:
4 Unknown  Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
Conditions: B-Cell Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: Bexxar
Outcome Measures: dose-limiting toxicity;   maximum tolerated dose;   overall response rate;   progression-free survival;   time to treatment failure
5 Unknown  Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bortezomib, Tositumomab
Outcome Measure: The primary objectives of this study are to determine: a) The appropriate doses of bortezomib and 131I-Tositumomab when used in combination. b) Toxicities of the combination treatment.
6 Recruiting Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Other: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
Outcome Measures: maximum tolerated dose (MTD);   3 year Event Free Survival (EFS);   3-year Event Free Survival (EFS);   rates of complete remission (CR);   Determine 3 year overall survival (OS).
7 Recruiting Imaging Based Dosimetry for Individualized Internal Emitter Therapy
Condition: Non-Hodgkin's Lymphoma
Intervention: Device: SPECT/CT imaging
Outcome Measures: Correlation between radiation absorbed dose to tumor and response or progression free survival;   Assess correlation between radiation absorbed dose to the bone marrow and hematologic toxicity.
8 Recruiting B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Rituximab
Outcome Measures: Symptom alleviation, as compared to baseline, measured by standardized self-reports and quality of life schemes;   Symptom alleviation, as compared to baseline, measured by standardized self-reports and quality of life schemes.
9 Recruiting Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Etanercept
Outcome Measures: Symptom alleviation within 12 months follow-up, as compared to baseline, measured by standardized self-reports and quality of life schemes.;   Symptom alleviation, as compared to baseline, measured by standardized self-reports and quality of life schemes.
10 Unknown  Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
Condition: Pemphigus
Intervention: Drug: Rituximab
Outcome Measure: Complete or partial remission off treatment (based on the consensus statement for pemphigus)
11 Unknown  Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: 90Yttrium Ibritumomab Tiuxetan (Zevalin)
Outcome Measure:
12 Recruiting Risk Stratified Sequential Treatment for CD20-positive PTLD
Conditions: PTLD;   Posttransplant Lymphoproliferative Disorder
Interventions: Drug: rituximab monotherapy;   Drug: sequential R-CHOP
Outcome Measures: The primary objective is the evaluation of the efficacy.For this aim the overall objective response rates after therapy = complete and partial response and the duration of the response will be measured.;   The secondary objective is to determine the adverse events and tolerability of rituximab and/or chemotherapy. Furthermore, the long-term safety will be determined, especially the frequency of complicating infections and the overall survival.
13 Recruiting Rituximab&Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL
Conditions: Primary Central Nervous System Lymphoma;   Brain and Central Nervous System Tumors;   Lymphoma
Interventions: Drug: Rituxan;   Drug: Carboplatin;   Drug: Methotrexate;   Drug: Sodium thiosulfate;   Drug: Neupogen;   Drug: Neulasta;   Drug: Leucovorin
Outcome Measures: Complete response rate;   Overall survival at 2 years;   Event-free survival at 2 years
14 Recruiting Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation
Condition: Poor Risk Chronic Lymphatic Leukemia
Intervention: Drug: Ofatumumab
Outcome Measures: Response rate after induction therapy;   rate of MRD-negative patients;   Rate of allogeneic HCT;   adverse drug reactions grade III/IV;   Overall, event-, and progression free survival;   relapse incidence;   non-relapse mortality;   Incidences of acute and chronic GVHD
15 Recruiting Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Outcome Measures: Time to treatment failure (TTF) measured from day 1 of course 1 of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy up to 3 years on study with life-long follow-up;   Complete response (CR) rate until first relapse;   Progression rate during treatment;   Survival;   Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored);   Disease-free survival measured from day 1 of course 1 of CHOP therapy;   Relapse-free survival of patients with complete response (CR) or unconfirmed complete response (CRu) following complete immunochemotherapy;   Safety (adverse events, serious adverse events) assessed at 3 months after completion of study treatment;   Consolidating radiotherapy
16 Unknown  Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
Conditions: Neuroblastoma;   Opsoclonus-Myoclonus
Intervention: Drug: anti-CD20 (Rituximab)
Outcome Measures: Feasibility and toxicity;   Response;   Pharmacokinetic data and HACA development in the pediatric population
17 Recruiting Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: Ofatumumab;   Drug: Etoposide;   Drug: Ifosfamid;   Drug: Mesna;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Leukovorin;   Drug: G-CSF
Outcome Measures: Response rate;   Progression-free survival;   Event-free survival;   Overall survival;   Number of participants with adverse events as a measure of safety and tolerability
18 Unknown  Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
Conditions: Burkitt Lymphoma;   B-Cell Acute Lymphoblastic Leukemia
Intervention: Drug: Chemotherapy-Rituximab combination
Outcome Measures: Overall survival;   Disease free survival;   Cumulative incidence of relapse;   Complete remission rate;   Toxicity
19 Recruiting Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab;   Biological: Rituximab
Outcome Measures: Progression-free survival;   complete response rate;   overall response rate;   duration of response;   time to next treatment;   overall survival;   infectious toxicity;   pharmacokinetics;   infusion related events;   hematological toxicity

These studies may lead to new treatments and are adding insight into Tositumomab etiology and treatment.

A major focus of Tositumomab research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Tositumomab